RTX vs SGMT · P/E 36, rev $88.60B vs rev $2.0M
RTX Corporation (RTX) versus Sagimet Biosciences Inc. Series A Common Stock (SGMT) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. SGMT currently screens at market cap $403.2M.
Not investment advice. Open the RTX and SGMT stock pages for the full models.
Not investment advice.